0 49

Cited 0 times in

Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients

DC FieldValueLanguage
dc.contributor.author이승규-
dc.contributor.author최은영-
dc.date.accessioned2021-01-19T07:57:18Z-
dc.date.available2021-01-19T07:57:18Z-
dc.date.issued2020-11-
dc.identifier.issn0392-856X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181390-
dc.description.abstractObjectives: To compare the occurrence of non-infectious uveitis based on the type of tumour necrosis factor (TNF) inhibitor used to manage spondyloarthritis in ankylosing spondylitis (AS) patients. Methods: The occurrence (new-onset and recurrence) of uveitis was reviewed retrospectively in AS patients receiving different TNF inhibitor therapies (adalimumab [ADA], infliximab [IFX], etanercept [ETN], and golimumab [GOL]) for the management of spondyloarthritis from 2005 to 2018. Kaplan-Meier analysis was performed to calculate the cumulative occurrence rates of uveitis during TNF inhibitor therapy, and a log-rank test was used to analyse differences between the survival curves. Multivariable Cox proportional-hazards models were used to compute hazard ratios (HRs) of different TNF agents for uveitis occurrence after adjusting for concurrent confounding factors. Results: The three-year cumulative occurrence rates of uveitis were significantly different according to the type of anti-TNFs used (23.1% in IFX, 18.5% in ETN, and 11.9% in ADA+GOL group) (p=0.020). The risk of new-onset uveitis was similar for different drugs. However, the IFX group showed a 5.4 times higher risk of recurrence than the ADA+GOL group (p=0.022). After adjusting for other confounding factors, IFX use was independently associated with a more frequent occurrence of uveitis in AS patients (HR=2.01; p=0.011). Conclusions: A significant number of AS patients who received anti-TNF therapy developed uveitis. Different types of anti-TNF drugs were associated with uveitis recurrence. Particularly, chimeric mouse-human monoclonal antibody (IFX) was found to increase the risk of uveitis occurrence compared to humanised monoclonal antibody (ADA or GOL).-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherClinical And Experimental Rheumatology S.A.S-
dc.relation.isPartOfCLINICAL AND EXPERIMENTAL RHEUMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdalimumab / adverse effects-
dc.subject.MESHCohort Studies-
dc.subject.MESHEtanercept / adverse effects-
dc.subject.MESHHumans-
dc.subject.MESHInfliximab / adverse effects-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSpondylitis, Ankylosing* / drug therapy-
dc.subject.MESHTumor Necrosis Factor Inhibitors / adverse effects*-
dc.subject.MESHTumor Necrosis Factor-alpha-
dc.subject.MESHUveitis* / chemically induced-
dc.titleUveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Ophthalmology (안과학교실)-
dc.contributor.googleauthorEun Young Choi-
dc.contributor.googleauthorMinwoo Lee-
dc.contributor.googleauthorChristopher Seungkyu Lee-
dc.contributor.localIdA02913-
dc.contributor.localIdA05056-
dc.contributor.localIdA05056-
dc.relation.journalcodeJ00555-
dc.identifier.eissn1593-098X-
dc.identifier.pmid32828140-
dc.identifier.urlhttps://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=32828140-
dc.contributor.alternativeNameLee, Christopher Seungkyu-
dc.contributor.affiliatedAuthor이승규-
dc.contributor.affiliatedAuthor최은영-
dc.contributor.affiliatedAuthor최은영-
dc.citation.volume38-
dc.citation.number6-
dc.citation.startPage1132-
dc.citation.endPage1137-
dc.identifier.bibliographicCitationCLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Vol.38(6) : 1132-1137, 2020-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.